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Transthyretin (TTR) is a 55 kDa protein responsible for
the transport of thyroid hormones and retinol in hu-
man serum. Misfolded forms of the protein are impli-
cated in the amyloid diseases familial amyloidotic
polyneuropathy and senile systemic amyloidosis. Its
folding properties and stabilization by ligands are of
current interest due to their importance in under-
standing and combating these diseases. To assist in
such studies we developed a method for the solid
phase synthesis of the monomeric unit of a TTR ana-
logue and its folding to form a functional 55 kDa
tetramer. The monomeric unit of the protein was
chemically synthesized in three parts, comprising
amino acid residues 1–51, 54–99 and 102–127, and lig-
ated using chemoselective thioether ligation chem-
istry. The synthetic protein was folded and assembled
to a tetrameric structure in the presence of the TTR’s
native ligand, thyroxine, as shown by gel filtration
chromatography, native gel electrophoresis, TTR anti-
body recognition and thyroid hormone binding. In the
current study the solution structure of the first of these
fragment peptides, TTR(1–51) is examined to deter-
mine its intrinsic propensity to form -sheet structure,
potentially involved in amyloid fibril formation by TTR.
Despite the presence of extensive -structure in the
native form of the protein, the N-terminal fragment
adopts an essentially random coil conformation in so-
lution. Clin Chem Lab Med 2002; 40(12):1221–1228
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Abbreviations: DIEA, diisopropylethylamine; DMF, N,N-
dimethyl formamide; ESMS, electrospray mass spec-
trometry; FAP, familial amyloidotic polyneuropathy;
HBTU, O-benzotriazole-N,N,N’, N’-tetramethyluronium
hexafluorophosphate; HF, hydrogen fluoride; NMR,
nuclear magnetic resonance; RP, reverse phase; sTTR,
synthetic transthyretin; T4, L-thyroxine; TFA, trifluo-
roacetic acid, TTR, transthyretin.
Introduction
Transthyretin (TTR) is responsible for the transport of
thyroid hormones such as 3,5,3’-triiodo-L-thyronine
(T3) and L-thyroxine (T4) in both the bloodstream and
the central nervous system (CNS). It is also involved in
the transport of retinol-binding protein (1, 2). TTR is a
55 kDa tetrameric protein and its structure and ligand
binding capabilities have been thoroughly character-
ized by X-ray crystallography (3–6). Each subunit con-
tains extensive β-sheet structure and is arranged within
a dimer of dimers to form a compact molecule with two
funnel-shaped hormone ligand binding sites, each de-
fined by a dimer-dimer interface. The thyroid hor-
mones bind deeply within the hydrophobic binding
channel, their iodine atoms residing in hydrophobic
pockets at two different binding sites within the chan-
nel (7). Upon binding of one T4 ligand, the binding
affinity for the second ligand is reduced substantially.
Retinol-binding protein, by contrast, binds on the outer
surface of TTR.
Figure 1 shows the structure of the TTR tetramer,
highlighting the central hormone-binding channel that
is formed at the dimer-dimer interface. One of the
monomers is highlighted separately to illustrate the
relative arrangement of monomers within the tetramer.
Residues 1–10 are disordered and not defined in the
crystal structure but it is clear that the structure is es-
sentially all β-sheet apart from a small helical region
near residues 74–82.
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Figure 1 Three-dimensional structure of transthyretin high-
lighting the secondary structure elements (PDB accession
number 1BM7). On the left is the structure of the tetramer,
highlighting the binding channel, and showing bound thyroid
hormone. On the right is a monomer unit, excluding the first
10 residues, which are disordered in the crystal structure.
TTR(1–51) contains three strands of β-sheet, which are shown
in a darker shade to the other strands in the monomer struc-
ture.
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The TTR tetramer is inherently very stable (1, 8), but
in some circumstances the protein undergoes a re-
arrangement to form amyloid fibrils. In diseases such
as senile systemic amyloidosis (SSA) and familial amy-
loidotic polyneuropathies (FAP), native and mutant
TTR, respectively, have been found to form long
β-sheet-based fibrillar structures (9–11). Amyloid has
been analyzed by X-ray diffraction and electron mi-
croscopy to reveal patterns indicative of stacked
β-sheet structure with strands perpendicular to the fib-
ril axis (11). These amyloid lesions accumulate in spe-
cific organs and are implicated in their dysfunction and
ultimately the death of the patients. There are now ap-
proximately 80 separate mutations that appear to be
associated with inherited amyloidosis (12–18). It is
thought that the underlying mechanism for TTR fibril
formation involves tetramer dissociation to a mono-
meric conformational intermediate, which self-assem-
bles to form amyloid fibrils. Any mutation or cellular
condition (such as low pH) that tends to destabilize the
tetramer can result in an increased propensity of the
protein to form amyloid fibrils (10, 13, 15).
Much recent interest has focused on the ligand bind-
ing properties of TTR because of the discovery that cer-
tain thyroid hormone competitors (e.g. 2,4,6-triiodo-
phenol) are able to decrease the tendency of TTR to
form amyloid fibrils (19, 20). Such ligands are reported
to act by binding deeply within the TTR-binding chan-
nel at both ligand-binding sites and inhibiting the for-
mation of amyloid by stabilizing the normal fold
against the pathogenic conformational change. A
range of non-steroidal anti-inflammatory drugs is cur-
rently being investigated for their ability to inhibit and
reverse amyloid formation (21).
Solid phase peptide synthesis provides a methodol-
ogy for studying the amyloidogenic propensity of dif-
ferent regions of TTR and for the analysis of ligand-
binding to synthetic mutants. In a recent report (22) we
demonstrated the total chemical synthesis of an ana-
logue of human TTR using a thioether-based strategy
for the sequential ligation of three peptide fragments of
TTR. We showed that this synthetic TTR (henceforth re-
ferred to as sTTR) could be successfully refolded and
reconstituted to form a 55 kDa tetrameric structure able
to bind the thyroid hormone T4. This represents one of
the largest active proteins made synthetically, and pro-
vides a methodology for future studies of TTR-ligand
interactions using nuclear magnetic resonance (NMR)
spectroscopic techniques. The approach also provides
fragments of TTR that can be used for a variety of stud-
ies, including an evaluation of the intrinsic propensity
of individual fragments of the protein to form a native
secondary structure. Such studies have the potential to
assist in understanding the folding properties of the
protein and provide insight into possible pathways
leading to amyloid deposition. 
In the current study we focus on a large fragment
corresponding to the N-terminal domain of TTR, re-
ferred to as TTR(1–51). NMR studies were used to ex-
amine the solution conformation of this fragment. The
location of this fragment in the structure of TTR is high-
lighted in bold in Figure 1. The region corresponding to
this peptide adopts exclusively a β-sheet structure in
the native protein, with the C-terminus of the fragment
being designed to occur at a natural turn in the struc-
ture. Since β-sheet is thought to be the major structural
element in amyloid fibrils, and since the termini of pro-
teins are the most likely to be first liberated during un-
folding events, we hypothesized that an N-terminal re-
gion with a high intrinsic propensity for the formation
of β-sheet structure would be interesting to study. Fur-
thermore, this peptide encompasses a number of
residues for which point mutations alter the amyloido-
genic potential of TTR. In particular, the mutation of
Val30 to Met is the most prevalent mutation associated
with FAP (23). 
A further motivation for the study of this peptide was
based on the finding that a range of small synthetic
peptides and proteolytically cleaved fragments of TTR
have been identified as components of amyloid fibrils.
For example, as noted by Hornberg et al. (6), the Lys-
48-Thr49 peptide bond of TTR is a potential serine
protease cleavage site, and both the N-terminal (Gly1-
Lys48) and C-terminal (Thr49-Glu 127) proteolytic frag-
ments of TTR have been found to be incorporated
together with wild-type TTR in fibrils. TTR(1–51) is a
slightly extended version of the former, raising the in-
terest in examining its conformational properties.
This article is a contribution based in part on a pre-
sentation made at the 1st International Congress on
Transthyretin in Health and Disease, in Strasbourg,
April 2002. The focus of that presentation was on the
chemical ligation strategy used to produce synthetic
TTR. Accordingly, the current article provides a brief
overview of that methodology, which has been de-
scribed in full elsewhere (22), but focuses mainly on
new experimental data on the solution properties of
the N-terminal fragment peptide, TTR(1–51). It was of
interest to determine whether this peptide would adopt
a stable monomeric β-sheet structure or indeed any
stable secondary structure in the absence of the re-




Trifluoroacetic acid (TFA), dichloromethane (DCM), N,N-di-
methyl formamide (DMF), and diisopropylethylamine (DIEA)
were from Auspep (Melbourne, Australia). O-benzotriazole-
N,N,N’, N’-tetramethyl-uronium hexafluorophosphate (HBTU)
was from Richelieu Biotechnologies (St. Hyacinth, Quebec,
Canada). Acetonitrile was from BDH Laboratory Supplies
(Poole, UK). Acetic acid and chloroacetic acid were from Ajax
chemicals (Auburn, Australia), diethyl ether from Fluka Bio-
chemicals (Melbourne, Australia) and mercaptoethanol from
Sigma (St. Louis, MO, USA). Ethanolamine, N,N-diisopropyl-
carbodiimide (DIC) and bromoacetic acid were from Aldrich
(Milwaukee, WI, USA). Hydrogen fluoride (HF) was purchased
from Boc Gases (Brisbane, Australia). The following N-Boc
protected L-amino acids Ala, Gly, Ile, Leu, Phe, Pro, Val, Arg (p-
toluenesulphonyl), Asp (O-cyclohexyl; OChx), Asn (xanthyl;
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Xanth), Glu (O-cyclohexyl; OChx), His (dinitrophenyl; DNP),
Lys (2-chlorobenzyloxycarbonyl; CIZ), Ser (benzyl; Bzl), Thr
(benzyl; Bzl), Trp (formyl; CHO), Tyr (2-bromobenzyloxycar-
bonyl; 2BrZ) were purchased either from NovaBiochem (La
Jolla, CA, USA) or Bachem (Bubendorf, Switzerland). Human
serum was supplied by the Red Cross Blood Bank, Melbourne,
Australia.
Equipment
Analytical and preparative HPLC was carried out using a Wa-
ters HPLC system comprised of model 600 solvent delivery
system, 600E controller and model 484 detector. Vydac C18
analytical columns (4.6 × 250 mm) at a flow rate of 1 ml/min
and semi-preparative (10 × 250 mm) at a flow rate of 3 ml/min
and preparative (22 × 250 mm) at a flow rate of 8 ml/min were
used. All peptides were purified using linear gradients of 0.1%
aqueous TFA (solvent A), 90% aqueous acetonitrile 0.09% TFA
(solvent B). Mass spectral data were collected using a Perkin
Elmer Sciex (Toronto, Canada) API III Biomolecular Mass Ana-
lyzer ion-spray mass spectrometer equipped with an ABI 140B
solvent delivery system. 
Peptide synthesis
The TTR fragment was synthesized as described previously
(22). It comprises the N-terminal 51 amino acids of TTR linked
to an alkyl thiol, with Cys10 replaced by Ala. The peptide was
synthesized using machine-assisted solid phase synthesis,
with the thiol linker attached to Boc-Gly-Pam resin. The
thioether resin was prepared according to the method of En-
glebretsen et al. (24) and the synthesis achieved using a rapid
HBTU in situ neutralization protocol (25). The average amino
acid coupling was 99.6% (1st coupling) for the synthesis,
which was routinely double coupled. 
Prior to HF cleavage, the DNP group of the histidine was re-
moved using 20% mercaptoethanol in 10% DIEA/DMF solu-
tion for 2–3 × 30 min treatments and the Trp formyl group was
removed using ethanolamine. The peptide resin was cleaved
using HF with p-cresol and p-thiocresol as scavengers at –5 to
–0 °C for 1–2 h. HF was removed in vacuo, the peptide tritu-
rated with cold diethyl ether (3 × 50 ml), and the precipitated
peptide was collected and dissolved in 50% acetonitrile with
0.1% TFA. The crude peptide was purified by reverse phase
(RP)-HPLC and fractions collected and analyzed by analytical
RP-HPLC and electrospray mass spectrometry (ESMS). The
purified peptide was characterized as the desired product by
ESMS (observed mass =5355±1.0 calculated for C236 H379 N66
O72 S2=5357.14 (average isotope composition)).
NMR spectroscopy
Samples for 1H NMR measurements contained ~1 mM
TTR(1–51) in 90% H2O/10% 2H2O (v/v) at pH 4. 2H2O was ob-
tained from Cambridge Isotope Laboratories (Woburn, MA,
USA). Spectra were recorded at 25 °C and 35 °C on a Bruker
ARX-500 spectrometer (Karlsruhe, Germany) equipped with a
shielded gradient unit. 2D NMR spectra were recorded in
phase-sensitive mode using time-proportional phase incre-
mentation for quadrature detection in the t1 dimension. The
2D experiments included TOCSY using a MLEV-17 spin lock
sequence with a mixing time of 80 ms, and NOESY with mix-
ing times of 200 ms and 250 ms. Solvent suppression for
NOESY and TOCSY experiments was achieved using a modi-
fied WATERGATE sequence. Spectra were routinely acquired
over 6024 Hz with 4096 complex data points in F2 and 512 in-
crements in the F1 dimension. 
Spectra were processed on a Silicon Graphics Indigo work-
station using XWINNMR (Bruker) software. The t1 dimension
was zero-filled to 2048 real data points, and 90 ° phase-shifted
sine bell window functions were applied prior to Fourier trans-
formation. Chemical shifts were referenced to external DSS at
0.00 ppm. 
Results 
The peptide chosen for study is a thiolated derivative of
the N-terminal domain of TTR that we synthesized orig-
inally as part of a strategy to make a synthetic variant of
TTR. Figure 2 shows the general strategy used to syn-
thesize sTTR based on the ligation of three fragment
peptides using thioether linkages. The choice of liga-
tion sites for the preparation of sTTR was based on
both the amino acid sequence and the known tertiary
structure of native TTR. The thioether linker spans a
distance equivalent to two amino acids, is highly flexi-
ble and non-functionalized. Gly-Gly sequences are thus
ideally suited as ligation points, but the TTR sequence
contains no Gly-Gly. Instead, Ser-Gly sites, which are
present at convenient positions, including two in loop
positions within the TTR structure (Figure 1) were cho-
sen as ligation points. Ser100-Gly101 occurs in the loop
between β-strands F and G, and Ser52-Gly53 in the loop
between β-strands C and D. Neither is close to the hor-
mone-binding site or at points of inter-subunit contact.
A third Ser-Gly site (Ser46-Gly47) occurs in the center of
β-strand C and was ruled out as a potential ligation
point due to the likely disruption of the β-sheet by a sur-
rogate amide.
The selection of Ser52-Gly53 and Ser100-Gly101 ligation
sites required the synthesis of three peptides of 51, 46
and 26 residues, as indicated in Figure 2. These were
then chemically joined using thioether linkers. The N-
Figure 2 Ligation scheme for the synthesis of transthyretin
showing the three-step process to give synthetic trans-
thyretin. Peptide I, representing TTR residues 102–127 was
prepared with an N-terminal bromoacetyl group and was
used to form a thioester bond with the free thiol of Peptide II
(Step1). Peptide II, representing TTR residues 54–99, was pre-
pared with both a C-terminal free thiol, and N-terminal
chloroacetyl group. Whilst the chloroacetyl group does not re-
act with free thiols, it is readily exchanged to an iodoacetyl
group (Step 2), which does. Thus, the first conjugated peptide
could readily be ligated to Peptide III, TTR residues 1–51 syn-
thesized with a C-terminal thiol, to create the complete sTTR
(Step 3).
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bromoacetylated 102–127 (peptide I) was first ligated
to the N-chloroacetylated, C-thiolated 54–99 (peptide
II). The purified chloroacetylated 54–127 peptide was
then exchanged to the iodoacetylated form and ligated
with C-thiolated 1–51 (peptide III) to produce fully lig-
ated 1–127 synthetic TTR. The ligated 1–127 peptide
was purified by RP-HPLC in excellent yield, and its iden-
tity confirmed by ESMS (22). 
The synthetic TTR spontaneously folded to its
tetramer complex in the presence of the ligand T4, in
0.075 M NH4HCO3 (22). Western analysis was em-
ployed to determine the subunit molecular mass and
confirm the recognition of the sTTR by anti-TTR anti-
serum. Synthetic TTR gave rise to bands correspond-
ing to the molecular masses of the sTTR monomer and
dimer. The correct folding and formation of the
tetramer was assessed by analyzing non-denaturing
polyacrylamide gel migration combined with a 125I-thy-
roxine-binding assay. The analysis of 125I-thyroxine
binding to proteins in human serum was used as the
reference and revealed the presence of thyroxine-bind-
ing globulin, albumin and TTR. The position of migra-
tion was almost identical to that in serum, indicating
that the tetrameric size, shape and charge distribution
of sTTR was almost identical to native TTR. 
These results showed that, when ligated, the syn-
thetic peptide fragments could adopt a structure simi-
lar to the native form and exhibit functional thyroid
hormone binding. The question we next wanted to ad-
dress was whether the entire TTR sequence was re-
quired for native secondary structure, or whether the
N-terminal domain alone would fold into native-like
structure. Peptide III (now referred to as TTR(1–51))
was therefore resynthesized as described in the Materi-
als and Methods. As was the case in the original stud-
ies, the only modification to the native TTR sequence
was the replacement of Cys10 with Ala to remove the
possibility of intermolecular disulfide bond formation.
Cys10 is the only Cys residue in native TTR. The re-
quired peptide was produced in good yield and its
identity was confirmed by mass spectrometry. The se-
quence is GPTGTGESKAPLMVKVLDAVRGSPAINVAV-
HVFRKAADDTWEPFASGKTSE-(NH-CH2-CH2-SH), with
the section in brackets corresponding to the thioether
linker.
NMR studies on TTR(1–51)
TTR(1–51) was readily soluble in water at millimolar
concentration and did not aggregate or precipitate over
a period of days used to record the NMR spectra. The
sample was prepared under a nitrogen atmosphere to
avoid potential oxidation reactions associated with the
terminal thiol moiety. A series of 1D, TOCSY and
NOESY spectra of TTR(1–51) were recorded and were
consistent with the presence of a single monomeric
species in solution. The NMR peaks were assigned us-
ing the standard sequential assignment method in
which amino acids were first assigned to residue type,
mainly using the TOCSY spectrum, and then these
were assigned to specific amino acids in the sequence
by reference to the NOESY spectrum. The assigned
chemical shifts are summarized in Table 1. 
Figure 3 shows the fingerprint region of the TOCSY
spectrum to illustrate the chemical shift dispersion of
the amide and αH protons and to summarize the as-
signments. The narrow range of NH chemical shifts
and the lack of substantially downfield or upfield
shifted αH chemical shifts provided the first indication
that the peptide was not highly structured. This was
confirmed by calculating the secondary αH shifts by
subtraction of random coil αH chemical shifts from the
observed shift for each residue. Helical regions of pep-
tides and proteins are characterized by a contiguous
series of negative secondary shifts, while β-sheet struc-
ture is typified by a series of positive secondary shifts
(26). Figure 4 shows that the measured secondary αH
shifts for TTR(1–51) are smaller than 0.1 ppm, apart
from a few residues.
Given this small range of αH secondary shifts it was
clear that TTR(1–51) adopts a random coil conforma-
tion and that it was not justified to attempt a full three-
dimensional structure calculation based on NOE data.
Figure 3 Fingerprint region of the TOCSY spectrum of
TTR(1–51) recorded on a Bruker ARX 500 spectrometer 298 K.
The dαN peaks are labeled with the single letter amino acid
code and residue number.
Figure 4 Secondary shift values for TTR(1–51) αH protons.
Deviations were calculated by subtracting random coil values
from the observed chemical shifts. Corrections for residues
preceding Pro were applied. Only five residues have chemical
shift deviations greater than 0.1 ppm, indicating a lack of or-
dered secondary structure. The asterisk indicates that signals
for Thr48 were not assigned.
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This was confirmed by the observation from the
NOESY spectrum that few medium or long range
NOES were present. The spectrum was dominated by
only intraresidue NOEs and NOEs between sequen-
tially adjacent residues.
The conclusion to emerge from these studies is that
the peptide adopts an essentially random coil structure
in solution and shows no signs of adopting the highly
β-sheet structure seen in the corresponding region of
the native protein. The various spectra were recorded
over the course of 5–6 days and there was no obvious
evidence of aggregation or fibril formation during this
time. This suggests that the peptide does not have a
strong intrinsic tendency to aggregate.
Table 1 Chemical shifts of TTR(1–51) at 298 K.
Residue NH αH βH Other
1 Pro n/a
2 Thr 8.19 4.39 4.27 γCH3 1.20
3 Gly 8.53 3.97
4 Thr 8.40 4.38 4.25 γCH3 1.24
5 Gly 8.36 3.97
6 Glu 8.22 4.41 2.12, 1.96 γCH2 2.44
7 Ser 8.38 4.43 3.86
8 Lys 8.35 4.34 1.42 γCH2, δCH2 1.68, εCH2 2.97
9 Ala 8.24 4.56 1.35
10 Pro 4.41 2.28, 1.89 γCH2 2.01, δCH2 3.76, 3.64
11 Leu 8.25 4.30 1.61 δCH3 0.9
12 Met 8.34 4.51 2.02 2.57, 2.50
13 Val 8.09 4.08 1.94 γCH3 0.84
14 Lys 8.35 4.36 1.45 γCH2, δCH2 1.68, εCH2 2.97
15 Val 8.17 4.06 2.04 γCH3 0.91
16 Leu 8.36 4.35 1.59 δCH3 0.91, 0.86
17 Asp 8.40 4.66 2.86, 2.78
18 Ala 8.17 4.27 1.36
19 Val 8.07 4.05 2.07 γCH3 0.93
20 Arg 8.41 4.33 1.85, 1.77 1.64, 3.19
21 Gly 8.37 3.97
22 Ser 8.20 4.77 3.82
23 Pro 4.43 2.29, 1.91 γCH2 2.01, δCH2 3.80, 3.70
24 Ala 8.31 4.28 1.22
25 Ile 8.04 4.15 1.84 γCH2 1.44, 1.16, γCH3 0.88
26 Asn 8.47 4.74 2.80, 2.72
27 Val 8.07 4.10 2.05 γCH3 0.92
28 Ala 8.28 4.32 1.33
29 Val 7.96 4.01 1.98 0.88
30 His 8.55 4.70 3.08
31 Val 8.09 4.06 2.02 γCH3 0.91
32 Phe 8.48 4.62 3.01 δH 7.23
33 Arg 8.21 4.29 1.74, 1.65 γCH2 1.51, δCH2 3.12
34 Lys 8.31 4.18 1.78, 1.37, 1.68, εCH2 2.97
35 Ala 8.36 4.27 1.38
36 Ala 8.31 4.28 1.36
37 Asp 8.30 4.65 2.86
38 Asp 8.32 4.69 2.83
39 Thr 7.98 4.26 4.19 1.14
40 Trp 8.09 4.61 3.22 NH 10.08, HD1 7.22, HE3 7.51, HZ2 7.45, HZ3 7.09, HH2 7.19
41 Glu 7.76 4.45 1.83, 1.62 2.23
42 Pro 4.31 2.13, 1.69 γCH2 1.84, δCH2 3.48, 3.37
43 Phe 7.96 4.55 3.10, 3.03 δH 7.22
44 Ala 8.07 4.29 1.32
45 Ser 8.18 4.36 3.87
46 Gly 8.40 3.96
47 Lys 8.16 4.38 1.85, 1.75 1.43 1.68, εCH2 2.97
48 Thr n/a
49 Ser 8.30 4.44 3.85
50 Glu 8.35 4.35 1.85, 1.72 2.00
51 Ser n/a
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Discussion
In the current study we synthesized a fragment corre-
sponding to the N-terminal domain region of TTR and
examined its solution properties. TTR(1–51) is soluble
at millimolar concentrations and forms an essentially
random coil conformation in solution showing that the
fragment itself does not have high intrinsic propensity
to form β-sheet structure. It thus appears that the pres-
ence of an extensive β-sheet structure in the intact pro-
tein relies on cooperative interactions with other parts
of the protein. The results also suggest that this frag-
ment of the protein is unlikely to be a nucleating region
for amyloid type structure as the fragment appeared to
be relatively stable in solution and did not aggregate
over the course of several days.
In previous studies the proteolytically derived N-ter-
minal (Gly1-Lys48) fragment of TTR and other peptide
fragments have been found to be incorporated to-
gether with wild-type TTR in fibrils (27, 28). The obser-
vation in the current study that the slightly longer
TTR(1–51) fragment does not appear to strongly ag-
gregate or form β-sheet structure suggests that the
proteolytic fragment is not likely to be a “seeding” in-
termediate for fibril formation. This is in agreement
with the suggestion by Hornberg et al. (6) that there are
currently no structural data that support such a propo-
sition.
Several shorter peptide fragments of TTR have been
shown to assemble into amyloid fibrils in vitro (27).
One of these, TTR(10–20), corresponds to just one of
the β-strands of TTR(1–51). In early structural studies
of this and other short peptides that line the pore of the
thyroxine-binding channel Jarvis et al. found that the
peptides adopt random coil conformations in 30% ace-
tonitrile (29) but spontaneously form β-sheet fibrils in
water (30). The dissociation of similar fibrils has more
recently been examined using TTR(10–19) in the pres-
ence of denaturants and co-solvents (31). The presence
of denaturants partially disrupted the fibrils to form
protofilaments. High concentrations of TFE also disso-
ciate TTR(10–19) fibrils to protofilaments but they also
slowly dissociate to monomeric soluble peptides with
extensive α-helical structure. The results suggest that
predominantly hydrophobic interactions are involved
in the assembly of TTR(10–19) into fibrils from protofil-
aments, whereas assembly of peptides into protofila-
ments involves both electrostatic and hydrophobic
forces (31). 
In another study of TTR fragments we examined the
peptide spanning the only helical region in TTR, corre-
sponding to residues 71–93. In the native structure of
TTR this sequence contains a helical region (residues
74–82) flanked by two extended regions that form an
antiparallel β-strand region within a β-sheet. While
there was no propensity for β-strand formation in the
peptide TTR(71–93), even when the ends were teth-
ered with a non-native disulfide bond (32), there was a
strong tendency for the helical region to form in aque-
ous solution (33). This suggests that while the helical
region of the protein has an intrinsic tendency to form
its native secondary structure, β-strand formation re-
lies much more heavily on its position in the context of
the whole protein.
These findings are consistent with comparable stud-
ies on other proteins. For example, extensive use of the
fragment dissection approach has been made to deter-
mine nucleation sites for the folding of T4 lysozyme
(34, 35). In that case it was found that peptide frag-
ments corresponding to helical regions in the intact
protein generally had an intrinsic tendency to be helical
in the isolated fragments, but this was not the case for
β-sheet regions. Different regions had differing intrin-
sic helical tendencies, allowing likely protein folding
initiation sites to be proposed (34). Conclusions on
folding initiation sites are much more difficult to draw
for highly β-sheet proteins such as TTR.
As noted earlier, mutations in TTR exist that cause or
suppress disease. The V30M mutation is the most
prevalent cause of FAP in heterozygotes, whereas a
T119M mutation on the second TTR allele protects
V30M carriers from disease (23). Incorporation of one
or more T119M TTR subunits into a predominantly
V30M tetramer strongly stabilized the mixed tetramer
against dissociation (23). The structural basis for the ef-
fects of the mutations is not yet understood. The ter-
tiary structure of native sTTR and many of its disease-
causing mutants has been determined, and structural
differences seen between TTR variants in early studies
(36–38) have been proposed to be significant for amy-
loid formation. However, a more recent study that de-
rived a 1.5 Å resolution structure of wild-type TTR and
compared it to a range of mutant structures proposed
that the structural differences are not significant (6). 
This recent finding and the current study are consis-
tent with the hypothesis of Kelly (15) that amyloid for-
mation by TTR may not be due to a major disruption of
secondary structure but rather to subtle perturbations
of structure which shift the subunit association equilib-
rium towards the monomer. The small ratio of mono-
meric TTR becomes involved in amyloid formation as a
complete unit. Fragments of TTR do not necessarily
have any intrinsic ability to form β-strands or partake in
amyloid formation.
This also explains the basis for the design of drugs to
decrease TTR amyloidosis. More than 50 small mole-
cules have been found that bind to and stabilize
tetrameric TTR, inhibiting amyloid fibril formation in
vitro (39). The molecules with the greatest therapeutic
potential are the non-steroidal anti-inflammatory
drugs, currently under investigation for their ability to
inhibit human TTR amyloid disease (21). These mole-
cules, which include flufenamic acid, diclofenac and
flurbiprofen, bind in the T4-binding site of TTR (40),
forming similar polar and non-polar contacts, as do the
natural ligands. These interactions are thought to sta-
bilize the native quaternary structure of TTR against
pH-mediated dissociation and conformational changes
associated with amyloid formation (20). Analogues of
diclofenac have recently been evaluated as TTR amy-
loid formation inhibitors with promising results (41).
However, further study is required to establish the ef-
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fectiveness of these analogues as therapeutics. Struc-
ture-based design has also been applied to the synthe-
sis of N-phenyl phenoxazine derivatives. One deriva-
tive was found by analytical ultracentrifugation to
block tetramer dissociation to the alternatively folded
amyloidogenic monomer (42).
In a seemingly analogous manner the native TTR lig-
and, T4, was required in our study for the correct fold-
ing of sTTR from its monomeric unfolded state to pro-
duce the 55 kDa tetrameric structure. T4 has previously
been reported to stabilize native TTR against acid de-
naturation leading to the formation of amyloid fibrils
(19). The integrity of the final product was confirmed by
native TTR antibody recognition and ligand-binding
studies. Since the binding site for thyroid hormone lig-
ands is formed only upon the formation of the
tetrameric species, ligand binding also demonstrated
tetramer formation. It is not known, however, whether
the sTTR tetramer forms and then is stabilized by T4 or
the tetramer spontaneously forms about the T4.
In conclusion, the chemical synthesis of a TTR ana-
logue has provided insight into the folding propensity
of the monomeric chain as well as an N-terminal frag-
ment of the molecule. It appears that the spontaneous
formation of the correct secondary and tertiary struc-
ture of sTTR is possible, even in the presence of the
flexible regions necessarily incurred at the ligation
sites. Correct folding occurs despite the fact that a ma-
jor region of the molecule (i.e. residues 1–51) shows no
intrinsic secondary structure formation. It was neces-
sary, however, for a strong TTR-binding ligand to be
present for the formation of the folded sTTR tetramer –
reflecting the inherent instability of the TTR monomer.
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